StreetInsider.com News Articles

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 21 Aug 2026 16:30:00 -0400

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company’s common stock (the “Inducement Awards”) to four new employees pursuant to the Company’s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee’s start date, and the remainder vesting in three equal annual installments thereafter (subject

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 21 Aug 2026 16:30:00 -0400

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 21 Aug 2026 16:30:00 -0400

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 21 Aug 2026 16:30:00 -0400

H.C. Wainwright Reiterates Buy Rating on Zevra Therapeutics, Inc. (ZVRA)

Thu, 20 Aug 2026 06:59:33 -0400

H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $26.00 price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA).

The analyst commented: "We recently hosted an investor dinner with the Zevra management team in Boston and came away increasingly positive across the three areas we believe matter most to the ZVRA story: the continued growth and durability of the U.S. MIPLYFFA opportunity, the probability of ultimately securing European approval, and the potential for celiprolol to become a meaningful second commercial asset. Management did not provide new guidance or incremental operating metrics at the dinner, however we had the opportunity to spend

Form 4 ZEVRA THERAPEUTICS, INC. For: Aug 14 Filed by: Thompson Rahsaan

Mon, 17 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26938417.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Aug 14 Filed by: Thompson Rahsaan

Mon, 17 Aug 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260817/26938417.html

Form 144 ZEVRA THERAPEUTICS, INC. Filed by: Thompson Rahsaan

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931620.html

Form 144 ZEVRA THERAPEUTICS, INC. Filed by: Thompson Rahsaan

Fri, 14 Aug 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260814/26931620.html

Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26927054.html

Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26927054.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Aug 10 Filed by: Watton Corey Michael

Wed, 12 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26913118.html

Form 4 ZEVRA THERAPEUTICS, INC. For: Aug 10 Filed by: Watton Corey Michael

Wed, 12 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260812/26913118.html

Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: FMR LLC

Thu, 06 Aug 2026 10:48:00 -0400

si-local-file:///var/storage/secattach/20260806/26881488.html

Form SCHEDULE 13G/A ZEVRA THERAPEUTICS, INC. Filed by: FMR LLC

Thu, 06 Aug 2026 10:48:00 -0400

si-local-file:///var/storage/secattach/20260806/26881488.html

Zevra Therapeutics, Inc. (ZVRA) PT Raised to $28 at Citizens

Thu, 06 Aug 2026 06:31:46 -0400

Citizens analyst Jason Butler raised the price target on Zevra Therapeutics, Inc. (NASDAQ: ZVRA) to $28.00 (from $25.00) while maintaining a Market Outperform rating.

Form 10-Q ZEVRA THERAPEUTICS, INC. For: Jun 30

Wed, 05 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260805/26875987.html

Form 10-Q ZEVRA THERAPEUTICS, INC. For: Jun 30

Wed, 05 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260805/26875987.html

Zevra Therapeutics, Inc. (ZVRA) Tops Q2 EPS by 3c

Wed, 05 Aug 2026 16:33:24 -0400

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q2 EPS of $0.14, $0.03 better than the analyst estimate of $0.11. Revenue for the quarter came in at $39.7 million versus the consensus estimate of $34.17 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

Form 8-K ZEVRA THERAPEUTICS, INC. For: Aug 05

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874490.html

Form 8-K ZEVRA THERAPEUTICS, INC. For: Aug 05

Wed, 05 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260805/26874490.html

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Wed, 05 Aug 2026 16:05:00 -0400

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA

53% increase in total net revenue over Q2 2025

Operational execution fueled strong cash position of $260.2 million

Company to host conference call and webcast TODAY, August 5, 2026, at 4:30 p.m. ET

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today reported its financial results for the second quarter ended June 30,

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Wed, 05 Aug 2026 16:05:00 -0400

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA

53% increase in total net revenue over Q2 2025

Operational execution fueled strong cash position of $260.2 million

Company to host conference call and webcast TODAY, August 5, 2026, at 4:30 p.m. ET

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Wed, 05 Aug 2026 16:05:00 -0400

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA

53% increase in total net revenue over Q2 2025

Operational execution fueled strong cash position of $260.2 million

Company to host conference call and webcast TODAY, August 5, 2026, at 4:30 p.m. ET

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Wed, 05 Aug 2026 16:05:00 -0400

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA

53% increase in total net revenue over Q2 2025

Operational execution fueled strong cash position of $260.2 million

Company to host conference call and webcast TODAY, August 5, 2026, at 4:30 p.m. ET